DelSiTech Announces an Exclusive Licensing and Collaboration Agreement with Visus Therapeutics for the Development of Long-acting Therapies in Ophthalmology

DelSiTech Announces an Exclusive Licensing and Collaboration Agreement with Visus Therapeutics for the Development of Long-acting Therapies in Ophthalmology

Turku, Finland – 19 August 2021: DelSiTech Ltd, the leader in silica based ophthalmic drug delivery technologies with its headquarters in Turku, Finland, and Visus Therapeutics, Inc., a Seattle-based American clinical-stage company developing innovative eye care solutions for patients globally, today announced an exclusive licensing and collaboration agreement pertaining to the development of a range of novel long-acting ocular therapeutics. The agreement, exclusive to therapeutic assets held by Visus Therapeutics, signals the continued commitment of both parties to develop leading solutions for patients around the world across six unique development programs targeting the management of ocular diseases of the back and front of the eye.

Read more…

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH